With around 1.8 million new cases per year, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer deaths globally. We are developing disposable, inexpensive optical biosensors for label-free detection of cancer biomarkers.
Our main value proposition is to improve early lung cancer diagnosis with rapid, accessible, and cost-effective diagnostic tools. These solutions enable timely follow-ups and support sustainability by improving public health, reducing healthcare costs, and expanding access in underserved communities. This approach will complement existing diagnostics, and our biosensor concept can also be adapted for early detection of other diseases, such as rheumatoid arthritis.
During the Biotech Booster program, we will validate our concept on cancer patient blood samples and build a solid market analysis and business model.
